1. Home
  2. FICO vs CANF Comparison

FICO vs CANF Comparison

Compare FICO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$1,679.91

Market Cap

41.2B

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.20

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FICO
CANF
Founded
1956
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.2B
2.9M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
FICO
CANF
Price
$1,679.91
$0.20
Analyst Decision
Buy
Strong Buy
Analyst Count
12
2
Target Price
$1,999.83
$3.25
AVG Volume (30 Days)
185.7K
10.1M
Earning Date
02-03-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
29.78
N/A
EPS
26.54
N/A
Revenue
$1,990,869,000.00
$560,000.00
Revenue This Year
$24.52
$461.72
Revenue Next Year
$16.94
N/A
P/E Ratio
$63.70
N/A
Revenue Growth
15.91
N/A
52 Week Low
$1,300.00
$0.17
52 Week High
$2,217.60
$2.33

Technical Indicators

Market Signals
Indicator
FICO
CANF
Relative Strength Index (RSI) 40.10 35.71
Support Level $1,701.49 $0.17
Resistance Level $1,779.01 $0.27
Average True Range (ATR) 45.07 0.03
MACD -9.99 -0.00
Stochastic Oscillator 6.18 21.60

Price Performance

Historical Comparison
FICO
CANF

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: